Skip to main content

DECODIFICANDO EL METABOLISMO DE LA CROMATINA EN EL CANCER DE MAMA

PID2019-110598GA-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACIO CENTRE DE REGULACIO GENOMICA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer

  • Pascual-Reguant, Laura
  • Serra Camprubí, Queralt
  • Datta, Debayan
  • Cianferoni, Damiano
  • Kourtis, Savvas
  • Gañez-Zapater, Antoni|||0000-0002-6852-4834
  • Cannatá, Chiara|||0000-0003-4807-4669
  • Espinar, Lorena|||0000-0003-3881-3886
  • Querol, Jessica|||0000-0002-0527-759X
  • García-López, Laura
  • Musa-Afaneh, Sara
  • Guirola, Maria
  • Gkanogiannis, Anestis|||0000-0002-6441-0688
  • Miró Canturri, Andrea
  • Guzmán, Marta|||0000-0002-0924-9887
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Herencia-Ropero, Andrea|||0009-0002-9448-1484
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Serra, Violeta|||0000-0001-6620-1065
  • Serrano, Luis|||0000-0002-5276-1392
  • Tian, Tian|||0000-0002-9906-0980
  • Peiró, Sandra|||0000-0001-9519-3877
  • Sdelci, Sara|||0000-0003-1330-4364
Triple-negative breast cancer (TNBC) often develops resistance to single-agent treatment, which can be circumvented using targeted combinatorial approaches. Here, we demonstrate that the simultaneous inhibition of LOXL2 and BRD4 synergistically limits TNBC proliferation in vitro and in vivo. Mechanistically, LOXL2 interacts in the nucleus with the short isoform of BRD4 (BRD4S), MED1, and the cell cycle transcriptional regulator B-MyB. These interactions sustain the formation of BRD4 and MED1 nuclear transcriptional foci and control cell cycle progression at the gene expression level. The pharmacological co-inhibition of LOXL2 and BRD4 reduces BRD4 nuclear foci, BRD4-MED1 colocalization, and the transcription of cell cycle genes, thus suppressing TNBC cell proliferation. Targeting the interaction between BRD4S and LOXL2 could be a starting point for the development of new anticancer strategies for the treatment of TNBC. Investigation of the molecular mechanisms underlying triple-negative breast cancer (TNBC) proliferation led to the identification of new therapeutic vulnerabilities.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer

  • Pascual-Reguant, Laura, 1990-
  • Datta, Debayan
  • Cianferoni, Damiano
  • Kourtis, Savvas
  • Gañez-Zapater, Antoni
  • Cannatá, Chiara
  • Espinar, Lorena
  • García López, Laura
  • Musa-Afaneh, Sara
  • Guirola, Maria
  • Gkanogiannis, Anestis
  • Miró Canturri, Andrea
  • Arribas, Joaquín
  • Serrano Pubull, Luis, 1982-
  • Sdelci, Sara
Triple-negative breast cancer (TNBC) often develops resistance to single-agent treatment, which can be circumvented using targeted combinatorial approaches. Here, we demonstrate that the simultaneous inhibition of LOXL2 and BRD4 synergistically limits TNBC proliferation in vitro and in vivo. Mechanistically, LOXL2 interacts in the nucleus with the short isoform of BRD4 (BRD4S), MED1, and the cell cycle transcriptional regulator B-MyB. These interactions sustain the formation of BRD4 and MED1 nuclear transcriptional foci and control cell cycle progression at the gene expression level. The pharmacological co-inhibition of LOXL2 and BRD4 reduces BRD4 nuclear foci, BRD4-MED1 colocalization, and the transcription of cell cycle genes, thus suppressing TNBC cell proliferation. Targeting the interaction between BRD4S and LOXL2 could be a starting point for the development of new anticancer strategies for the treatment of TNBC., We thank Pharmaxis for the supply of PXS LOXL2 inhibitors. SS is supported by the Plan Estatal de I + D + I (COMBAT PID2019‐110598GA‐I00), and the ERC Starting Grant (ERC‐StG‐852343‐EPICAMENTE). LP‐R is supported by the Juan de la Cierva‐Formación fellowship (FJC2019‐040598‐I) and Fundación Franscico Cobos fellowship. TVT is supported by Plan Estatal de I + D + I (PID2019‐108008RJ‐I00), AECC (INVES20036TIAN), and a Ramón y Cajal investigator contract (RYC2020‐029098‐I). DC is supported by the la Caixa Foundation PhD fellowship (ID 100010434; fellowship code LCF/BQ/DI19/11730061).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Nuclear localization of MTHFD2 is required for correct mitosis progression

  • Pardo-Lorente, Natalia
  • Gkanogiannis, Anestis
  • Cozzuto, Luca
  • Gañez-Zapater, Antoni
  • Espinar, Lorena
  • Ghose, Ritobrata
  • Severino, Jacqueline, 1990-
  • García-López, Laura
  • Aydin, Rabia Gül
  • Martin, Laura
  • Neguembor, Maria Victoria
  • Darai, Evangelia
  • Cosma, Maria Pia
  • Batlle-Morera, Laura
  • Ponomarenko, Julia
  • Sdelci, Sara
Subcellular compartmentalization of metabolic enzymes establishes a unique metabolic environment that elicits specific cellular functions. Indeed, the nuclear translocation of certain metabolic enzymes is required for epigenetic regulation and gene expression control. Here, we show that the nuclear localization of the mitochondrial enzyme methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) ensures mitosis progression. Nuclear MTHFD2 interacts with proteins involved in mitosis regulation and centromere stability, including the methyltransferases KMT5A and DNMT3B. Loss of MTHFD2 induces severe methylation defects and impedes correct mitosis completion. MTHFD2 deficient cells display chromosome congression and segregation defects and accumulate chromosomal aberrations. Blocking the catalytic nuclear function of MTHFD2 recapitulates the phenotype observed in MTHFD2 deficient cells, whereas restricting MTHFD2 to the nucleus is sufficient to ensure correct mitotic progression. Our discovery uncovers a nuclear role for MTHFD2, supporting the notion that translocation of metabolic enzymes to the nucleus is required to meet precise chromatin needs., We acknowledge support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), and the Generalitat de Catalunya through the CERCA programme. We are grateful to the CRG Core Technologies Programme for their support and assistance in this work. We would like to thank the CRG and CNAG Sequencing Facilities (Barcelona, Spain) for all next-generation sequencing, the CRG Proteomics Facility (Barcelona, Spain) for the MTHFD2 interactome analysis, the CRG Flow Cytometry Facility (Barcelona, Spain) for the sorting, the IMIM Platform for molecular cytogenetics (Barcelona, Spain) for the karyotype analysis, and MARbiobank for provision of patient samples for organoid generation. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech). We would like to thank Prof. Thomas Helleday for providing the MTHFD2 inhibitor TH9619 and for the fruitful discussions. N.P.L. was supported by a Boehringer Ingelheim Fonds Ph.D. fellowship. This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 852343, ERC-StG-852343-EPICAMENTE) and from a Spanish Plan Estatal grant (Ministerio de Ciencia e Innovación, Project PID2019-110598GA-I00 funded by MICIU/AEI /10.13039/501100011033).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Nuclear IMPDH2 controls the DNA damage response by modulating PARP1 activity

  • Espinar, Lorena
  • Garcia-Cao, Marta
  • Schmidt, Alisa
  • Kourtis, Savvas
  • Gañez-Zapater, Antoni
  • Aranda Vallejo, Carla
  • Ghose, Ritobrata
  • García-López, Laura
  • Sheraj, Ilir
  • Pardo-Lorente, Natalia
  • Bantulà, Marina
  • Pascual-Reguant, Laura, 1990-
  • Darai, Evangelia
  • Guirola, Maria
  • Montero, Joan
  • Sdelci, Sara
Nuclear metabolism and DNA damage response are intertwined processes, but the precise molecular links remain elusive. Here, we explore this crosstalk using triple-negative breast cancer (TNBC) as a model, a subtype often prone to DNA damage accumulation. We show that the de novo purine synthesis enzyme IMPDH2 is enriched on chromatin in TNBC compared to other subtypes. IMPDH2 chromatin localization is DNA damage dependent, and IMPDH2 repression leads to DNA damage accumulation. On chromatin, IMPDH2 interacts with and modulates PARP1 activity by controlling the nuclear availability of NAD+ to fine-tune the DNA damage response. However, when IMPDH2 is restricted to the nucleus, it depletes nuclear NAD+, leading to PARP1 cleavage and cell death. Our study identifies a non-canonical nuclear role for IMPDH2, acting as a convergence point of nuclear metabolism and DNA damage response., The authors would like to thank the Genomics Unit at the CRG for assistance with the sequencing, the CRG Proteomics Facility (Barcelona, Spain) for the chromatome MS analysis, the CRG Flow Cytometry Facility (Barcelona, Spain) for the cell cycle analysis, Dr. Ivan Perez-Nuñez from Dr. Toni Celià-Terrassa group (IMIM, Barcelona, Spain) for helping with the IHC analysis. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech). We acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), and the Generalitat de Catalunya through the CERCA program. N.P.L. is supported by a Boehringer Ingelheim Fonds Ph.D. fellowship. L.P.R. is supported by a Fundación Francisco Cobo (Eduardo Gallego) postdoctoral fellowship. The Sdelci lab’s contributions to this study have received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement No 852343), and from the Spanish Plan Estatal grants (Ministerio de Ciencia e Innovación, PID2019-110598GA-I00/AEI/10.13039/501100011033 and PID2022-141740NB-I00 funded by MICIU /AEI /10.13039/501100011033 / FEDER, UE) and from Fundación BBVA under Beca Leonardo a Investigadores y Creadores Culturales 2022 (LEO22-2-2290-BBM-BAS-167).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Nuclear localization of MTHFD2 is required for correct mitosis progression

  • Pardo-Lorente, Natalia
  • Gkanogiannis, Anestis
  • Cozzuto, Luca
  • Gañez Zapater, Antoni
  • Espinar, Lorena
  • Ghose, Ritobrata
  • Severino, Jacqueline
  • García-López, Laura
  • Gül Aydin, Rabia
  • Martin, Laura
  • Neguembor, Maria Victoria
  • Darai, Evangelia
  • Cosma, Maria Pia
  • Batlle-Morera, Laura
  • Ponomarenko, Julia
  • Sdelci, Sara
Subcellular compartmentalization of metabolic enzymes establishes a unique metabolic environment that elicits specific cellular functions. Indeed, the nuclear translocation of certain metabolic enzymes is required for epigenetic regulation and gene expression control. Here, we show that the nuclear localization of the mitochondrial enzyme methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) ensures mitosis progression. Nuclear MTHFD2 interacts with proteins involved in mitosis regulation and centromere stability, including the methyltransferases KMT5A and DNMT3B. Loss of MTHFD2 induces severe methylation defects and impedes correct mitosis completion. MTHFD2 deficient cells display chromosome congression and segregation defects and accumulate chromosomal aberrations. Blocking the catalytic nuclear function of MTHFD2 recapitulates the phenotype observed in MTHFD2 deficient cells, whereas restricting MTHFD2 to the nucleus is sufficient to ensure correct mitotic progression. Our discovery uncovers a nuclear role for MTHFD2, supporting the notion that translocation of metabolic enzymes to the nucleus is required to meet precise chromatin needs., We acknowledge support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), and the Generalitat de Catalunya through the CERCA programme. We are grateful to the CRG Core Technologies Programme for their support and assistance in this work. We would like to thank the CRG and CNAG Sequencing Facilities (Barcelona, Spain) for all next-generation sequencing, the CRG Proteomics Facility (Barcelona, Spain) for the MTHFD2 interactome analysis, the CRG Flow Cytometry Facility (Barcelona, Spain) for the sorting, the IMIM Platform for molecular cytogenetics (Barcelona, Spain) for the karyotype analysis, and MARbiobank for provision of patient samples for organoid generation. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech). We would like to thank Prof. Thomas Helleday for providing the MTHFD2 inhibitor TH9619 and for the fruitful discussions. N.P.L. was supported by a Boehringer Ingelheim Fonds Ph.D. fellowship. This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 852343, ERC-StG-852343-EPICAMENTE) and from a Spanish Plan Estatal grant (Ministerio de Ciencia e Innovación, Project PID2019-110598GA-I00 funded by MICIU/AEI /10.13039/501100011033)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2020-001049-S)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Nuclear IMPDH2 controls the DNA damage response by modulating PARP1 activity

  • Espinar, Lorena
  • Garcia-Cao, Marta
  • Schmidt, Alisa
  • Kourtis, Savvas
  • Gañez-Zapater, Antoni
  • Aranda Vallejo, Carla
  • Ghose, Ritobrata
  • García-López, Laura
  • Sheraj, Ilir
  • Pardo Lorente, Natalia
  • Bantulà, Marina
  • Pascual-Reguant, Laura, 1990-
  • Darai, Evangelia
  • Guirola, Maria
  • Montero, Joan
  • Sdelci, Sara
Nuclear metabolism and DNA damage response are intertwined processes, but the precise molecular links remain elusive. Here, we explore this crosstalk using triple-negative breast cancer (TNBC) as a model, a subtype often prone to DNA damage accumulation. We show that the de novo purine synthesis enzyme IMPDH2 is enriched on chromatin in TNBC compared to other subtypes. IMPDH2 chromatin localization is DNA damage dependent, and IMPDH2 repression leads to DNA damage accumulation. On chromatin, IMPDH2 interacts with and modulates PARP1 activity by controlling the nuclear availability of NAD+ to fine-tune the DNA damage response. However, when IMPDH2 is restricted to the nucleus, it depletes nuclear NAD+, leading to PARP1 cleavage and cell death. Our study identifies a non-canonical nuclear role for IMPDH2, acting as a convergence point of nuclear metabolism and DNA damage response., The authors would like to thank the Genomics Unit at the CRG for assistance with the sequencing, the CRG Proteomics Facility (Barcelona, Spain) for the chromatome MS analysis, the CRG Flow Cytometry Facility (Barcelona, Spain) for the cell cycle analysis, Dr. Ivan Perez-Nuñez from Dr. Toni Celià-Terrassa group (IMIM, Barcelona, Spain) for helping with the IHC analysis. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech). We acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), and the Generalitat de Catalunya through the CERCA program. N.P.L. is supported by a Boehringer Ingelheim Fonds Ph.D. fellowship. L.P.R. is supported by a Fundación Francisco Cobo (Eduardo Gallego) postdoctoral fellowship. The Sdelci lab’s contributions to this study have received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement No 852343), and from the Spanish Plan Estatal grants (Ministerio de Ciencia e Innovación, PID2019-110598GA-I00/AEI/10.13039/501100011033 and PID2022-141740NB-I00 funded by MICIU /AEI /10.13039/501100011033 / FEDER, UE) and from Fundación BBVA under Beca Leonardo a Investigadores y Creadores Culturales 2022 (LEO22-2-2290-BBM-BAS-167).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Nuclear localization of MTHFD2 is required for correct mitosis progression

  • Pardo Lorente, Natalia
  • Gkanogiannis, Anestis
  • Cozzuto, Luca
  • Gañez-Zapater, Antoni
  • Espinar, Lorena
  • Ghose, Ritobrata
  • Severino, Jacqueline, 1990-
  • García-López, Laura
  • Aydin, Rabia Gül
  • Martin, Laura
  • Neguembor, Maria Victoria
  • Darai, Evangelia
  • Cosma, Maria Pia
  • Batlle-Morera, Laura
  • Ponomarenko, Julia
  • Sdelci, Sara
Subcellular compartmentalization of metabolic enzymes establishes a unique metabolic environment that elicits specific cellular functions. Indeed, the nuclear translocation of certain metabolic enzymes is required for epigenetic regulation and gene expression control. Here, we show that the nuclear localization of the mitochondrial enzyme methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) ensures mitosis progression. Nuclear MTHFD2 interacts with proteins involved in mitosis regulation and centromere stability, including the methyltransferases KMT5A and DNMT3B. Loss of MTHFD2 induces severe methylation defects and impedes correct mitosis completion. MTHFD2 deficient cells display chromosome congression and segregation defects and accumulate chromosomal aberrations. Blocking the catalytic nuclear function of MTHFD2 recapitulates the phenotype observed in MTHFD2 deficient cells, whereas restricting MTHFD2 to the nucleus is sufficient to ensure correct mitotic progression. Our discovery uncovers a nuclear role for MTHFD2, supporting the notion that translocation of metabolic enzymes to the nucleus is required to meet precise chromatin needs., We acknowledge support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), and the Generalitat de Catalunya through the CERCA programme. We are grateful to the CRG Core Technologies Programme for their support and assistance in this work. We would like to thank the CRG and CNAG Sequencing Facilities (Barcelona, Spain) for all next-generation sequencing, the CRG Proteomics Facility (Barcelona, Spain) for the MTHFD2 interactome analysis, the CRG Flow Cytometry Facility (Barcelona, Spain) for the sorting, the IMIM Platform for molecular cytogenetics (Barcelona, Spain) for the karyotype analysis, and MARbiobank for provision of patient samples for organoid generation. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech). We would like to thank Prof. Thomas Helleday for providing the MTHFD2 inhibitor TH9619 and for the fruitful discussions. N.P.L. was supported by a Boehringer Ingelheim Fonds Ph.D. fellowship. This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 852343, ERC-StG-852343-EPICAMENTE) and from a Spanish Plan Estatal grant (Ministerio de Ciencia e Innovación, Project PID2019-110598GA-I00 funded by MICIU/AEI /10.13039/501100011033).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer

  • Pascual-Reguant, Laura, 1990-
  • Datta, Debayan
  • Cianferoni, Damiano
  • Kourtis, Savvas
  • Gañez-Zapater, Antoni
  • Cannatá, Chiara
  • Espinar, Lorena
  • García López, Laura
  • Musa-Afaneh, Sara
  • Guirola, Maria
  • Gkanogiannis, Anestis
  • Miró Canturri, Andrea
  • Arribas, Joaquín
  • Serrano Pubull, Luis, 1982-
  • Sdelci, Sara
Triple-negative breast cancer (TNBC) often develops resistance to single-agent treatment, which can be circumvented using targeted combinatorial approaches. Here, we demonstrate that the simultaneous inhibition of LOXL2 and BRD4 synergistically limits TNBC proliferation in vitro and in vivo. Mechanistically, LOXL2 interacts in the nucleus with the short isoform of BRD4 (BRD4S), MED1, and the cell cycle transcriptional regulator B-MyB. These interactions sustain the formation of BRD4 and MED1 nuclear transcriptional foci and control cell cycle progression at the gene expression level. The pharmacological co-inhibition of LOXL2 and BRD4 reduces BRD4 nuclear foci, BRD4-MED1 colocalization, and the transcription of cell cycle genes, thus suppressing TNBC cell proliferation. Targeting the interaction between BRD4S and LOXL2 could be a starting point for the development of new anticancer strategies for the treatment of TNBC., We thank Pharmaxis for the supply of PXS LOXL2 inhibitors. SS is supported by the Plan Estatal de I + D + I (COMBAT PID2019‐110598GA‐I00), and the ERC Starting Grant (ERC‐StG‐852343‐EPICAMENTE). LP‐R is supported by the Juan de la Cierva‐Formación fellowship (FJC2019‐040598‐I) and Fundación Franscico Cobos fellowship. TVT is supported by Plan Estatal de I + D + I (PID2019‐108008RJ‐I00), AECC (INVES20036TIAN), and a Ramón y Cajal investigator contract (RYC2020‐029098‐I). DC is supported by the la Caixa Foundation PhD fellowship (ID 100010434; fellowship code LCF/BQ/DI19/11730061).